Some Assembly Required: Solving The Puzzle Of Real-World Data/Evidence

The discourse surrounding real-world data, encompassing the vast expanse of information derived from electronic medical records, claims, prescription databases, and various other sources, is gaining substantial traction. This surge in interest is fueled by the industry's and regulators' growing inclination to leverage real-world data as a credible source of evidence in both clinical research and the development of therapeutic products.

In this context, Julie O'Brien, the Global Forum Regional Editor for Europe representing Pfizer, takes the helm in delving into the current landscape and the potential future trajectories of real-world data and evidence. The exploration unfolds through the dual lenses of the regulated entities and the regulators, offering a comprehensive perspective. Collaborating in this insightful journey are Jennifer Dudinak from Bristol Myers Squibb and Max Wegner from Bayer AG, contributing their expertise to enrich the discussion.

As stakeholders navigate this evolving terrain, understand why the synergy between industry practitioners and regulatory bodies is pivotal, shaping the narrative of how real-world data can truly emerge as a cornerstone in advancing clinical research and enhancing the landscape of therapeutic product development.